CRANBURY, N.J. - Palatin Technologies (NYSE:PTN), Inc. (NYSE American: PTN) has reached a significant milestone in the development of its dry eye disease (DED) treatment, PL9643, with the U.S. Food and Drug Administration (FDA) confirming the acceptability of its Phase 3 clinical trial protocols and endpoints. The company announced today that the FDA has agreed on the regulatory path forward for the New Drug Application (NDA) submission of PL9643, following positive outcomes from recent discussions.
The planned Phase 3 clinical trials, MELODY-2 and MELODY-3, aim to evaluate the efficacy and safety of PL9643 for DED treatment, with patient enrollment expected to commence in the fourth quarter of 2024. If the trials proceed as anticipated, topline results could be available by the end of 2025, potentially leading to an NDA submission in the first half of 2026.
Palatin's optimism is bolstered by the success of its first Phase 3 study, MELODY-1, completed in February 2024. The study showed promising results, with statistical significance achieved in the co-primary symptom endpoint of pain and several secondary symptom endpoints, indicating rapid onset of efficacy. Notably, the treatment demonstrated an excellent safety and tolerability profile.
DED is a prevalent inflammatory condition affecting millions worldwide, causing discomfort and potential vision damage. Current treatments often fall short in effectiveness and tolerability, highlighting the need for improved therapeutic options. Palatin's PL9643 targets the melanocortin receptor system, which plays a role in inflammation and immune responses, and could offer a differentiated approach to managing DED symptoms.
The company's strategy involves developing innovative medicines and forming marketing collaborations to maximize commercial potential. The positive feedback from the FDA represents a crucial step in bringing PL9643 closer to market, where it could provide relief for the millions suffering from DED.
This development is based on a press release statement and reflects the company's ongoing efforts to address significant unmet medical needs in the treatment of diseases like dry eye disease.
In other recent news, Palatin Technologies has embarked on a Phase II clinical trial for a potential obesity treatment, combining Bremelanotide with Tirzepatide. The study, BMT-801, is expected to enroll up to 60 participants across four U.S. sites, with full patient enrollment anticipated by the third quarter of 2024. Palatin's Q3 fiscal year 2024 results showed a net loss of $8.4 million, with operating expenses rising to $9.2 million due to investments in Melanocortin receptor programs.
Furthermore, Palatin secured approximately $6.1 million from the exercise of warrants, which will be allocated for working capital and other corporate purposes. The company's annual stockholders' meeting resulted in the election of seven directors, ratification of KPMG LLP as the public accounting firm, and approval of an amendment to its 2011 Stock Incentive Plan.
H.C. Wainwright maintained its Buy rating for Palatin following the commencement of another Phase 2 clinical trial focused on the treatment of erectile dysfunction. Palatin also plans to submit an Investigational New Drug application for a new co-formulation combining bremelanotide with a PDE5i, with a potential Phase 3 clinical trial projected to begin in the first half of 2025. These developments indicate Palatin's ongoing commitment to clinical programs and regulatory engagement.
InvestingPro Insights
As Palatin Technologies, Inc. (NYSE American: PTN) moves forward with its Phase 3 clinical trials for the dry eye disease treatment PL9643, recent data and analysis from InvestingPro shed light on the company's financial health and market performance. According to InvestingPro Tips, analysts have revised their earnings forecasts downwards for the upcoming period and anticipate a sales decline in the current year. This outlook is critical for investors to consider as it may impact the company's ability to fund ongoing clinical trials and potential commercialization efforts.
InvestingPro Data indicates that Palatin's revenue in the last twelve months as of Q3 2024 stood at $5.9 million, with a significant revenue growth of 52.8%. However, the company's gross profit margin was reported at -329.27%, indicating that despite growing revenues, the cost of goods sold significantly outweighs the revenue generated, leading to a gross profit of -$19.43 million. Additionally, the operating income margin was at -555.24%, highlighting operational challenges.
The company's stock performance has also been under scrutiny, with a 1-month price total return showing a decrease of 12.35%, and a 6-month price total return marking a decline of 39.18%. These figures provide a glimpse into the volatility and investor sentiment surrounding Palatin Technologies in the short term.
For investors seeking to delve deeper into Palatin's financial metrics and potential investment risks, InvestingPro offers additional insights. There are currently six more InvestingPro Tips available for PTN, including analysis on profitability and debt levels, which can be accessed by visiting https://www.investing.com/pro/PTN. These tips could be particularly relevant for understanding the broader financial context in which Palatin operates as it navigates the clinical and regulatory milestones ahead.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.